Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective

JACC. CardioOncology · Published 2026-08-01 · DOI 10.1016/j.jaccao.2026.06.008

Free full text

Authors (3)

Giulia Guerra, George Bianco, Alessandra Ghigo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Guerra, G., Bianco, G., Ghigo, A. (2026). Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective. JACC. CardioOncology. https://doi.org/10.1016/j.jaccao.2026.06.008

Related articles

• CRISPR/Cas9 Screens Implicate RARA and SPNS1 in Doxorubicin Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal
• Sacubitril/Valsartan in Anthracycline-Treated Patients · JACC. CardioOncology · 2026 · Same journal
• Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia · JACC. CardioOncology · 2026 · Same journal
• Screened But Unproven · JACC. CardioOncology · 2026 · Same journal
• Treatment and Outcomes in Myocardial Infarction and Cancer—A German Real-Life Analysis · JACC. CardioOncology · 2026 · Same journal
• Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension · JACC. CardioOncology · 2026 · Same journal
• The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM · JACC. CardioOncology · 2026 · Same journal
• Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity · JACC. CardioOncology · 2026 · Same journal
• Proactive Surveillance for ICI Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal
• Reply · JACC. CardioOncology · 2026 · Same journal